Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetcare ltd.* - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 200 mg/50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 40 mg/10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - sýklalyf fyrir almenn nota, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea* - cefuroximum natríum - stungulyfsstofn, lausn - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada nordic aps. - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g